Neurodevelopmental Effects of Fetal Antiepileptic Drug Exposure

Drug Safety

Volumn 38, Issue 3, 2015, Pages 271-278

  Velez Ruiz, Naymee J ^a   Meador, Kimford J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

CHEMICALLY INDUCED; DRUG EFFECTS; EPILEPSY; FEMALE; FETUS DEVELOPMENT; HUMAN; NEURODEVELOPMENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE;

ANTICONVULSANTS; EPILEPSY; FEMALE; FETAL DEVELOPMENT; HUMANS; NEURODEVELOPMENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84939937000     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0269-9     Document Type: Review

References (50)

1. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2001;70(1):15–21.
2. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2004;75(11):1575–83.
3. Adams J, Vorhees CV, Middaugh LD. Developmental neurotoxicity of anticonvulsants: human and animal evidence on phenytoin. Neurotoxicol Teratol. 1990;12(3):203–14.
4. Bittigau P, Sifringer M, Genz K, et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA. 2002;99(23):15089–94.
5. Bittigau P, Sifringer M, Ikonomidou C. Antiepileptic drugs and apoptosis in the developing brain. Ann N Y Acad Sci. 2003;993:103–14.
6. Bromley RL, Mawer GE, Briggs M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84(6):637–43.
7. Bromley RL, Mawer G, Love J, et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia. 2010;51(10):2058–65.
8. Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309:1696–703.
9. Cohen MJ, Meador KJ, Browning N, et al. Fetal antiepileptic drug exposure: motor, adaptive, and emotional/behavioral functioning at age 3 years. Epilepsy Behav. 2011;22(2):240–6.
10. Cohen MJ, Meador KJ, Browning N, et al. Fetal antiepileptic drug exposure: adaptive and emotional/behavioral functioning at age 6 years. Epilepsy Behav. 2013;29(2):308–15.
11. Cummings C, Stewart M, Stevenson M, et al. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child. 2011;96(7):643–7.
12. Eriksson K, Viinikainen K, Monkkonen A, et al. Children exposed to valproate in utero—population based evaluation of risks and cofounding factors for long-term neurocognitive development. Epilepsy Res. 2005;65(3):189–200.
13. Farwell JR, Lee YJ, Hirtz DG, et al. Phenobarbital for febrile seizures—effects on intelligence and on seizure recurrence. N Engl J Med. 1990;322(6):364–9.
14. Finnell RH, Shields HE, Taylor SM, et al. Strain differences in phenobarbital-induced teratogenesis in mice. Teratology. 1987;35(2):177–85.
15. Forcelli PA, Janssen MJ, Vicini S, et al. Neonatal exposure to antiepileptic drugs disrupts striatal synaptic development. Ann Neurol. 2012;72(3):363–72.
16. Forcelli PA, Kim J, Kondratyev A, et al. Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain. Epilepsia. 2011;52(12):e207–11.
17. Forcelli PA, Koziowski R, Snyder C, et al. Effects of neonatal antiepileptic drug exposure on cognitive, emotional, and motor function in adult rats. J Pharmacol Exp. 2012;340(3):558–66.
18. Gaily E, Kantola-Sorsa E, Hillesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004;62(1):28–32.
19. Forsberg L, Wide K, Kallen B. School performance at age 16 in children exposed to antiepileptic drugs in utero- a population-based study. Epilepsia. 2011;52(2):364–9.
20. Gedzelman ER, Meador KJ. Neurological and psychiatric sequelae of developmental exposure to antiepileptic drugs. Front Neurol. 2012;3:182.
21. Hanson JW, Myrianthopoulos NC, Harvey MA, et al. Risks of the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr. 1976;89(4):662–8.
22. Harden CL, Meador KJ, Pennell PB, et al. Management issues for women with epilepsy—focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia. 2009;50(5):1237–46.
23. Katz I, Kim J, Gale K, et al. Effects of lamotrigine alone and in combination with MK-801, phenobarbital, or phenytoin on cell death in the neonatal rat brain. J Pharmacol Exp Ther. 2007;322(2):494–500.
24. Kim J, Kondratyev A, Gale K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J Pharmacol Exp Ther. 2007;323(1):165–73.
25. Koch S, Titze K, Zimmermann RB, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia. 1999;40(9):1237–43.
26. Losche G, Steinhausen HC, Koch S, et al. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr. 1994;83(9):961–6.
27. Manent JB, Jorquera I, Mazzucchelli I, et al. Feta exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. Epilepsia. 2007;48(4):684–93.
28. McVearry KM, Gaillard WD, Van Meter J, et al. A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. Epilepsy Behav. 2009;16(4):609–16.
29. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med. 2009;360(16):1597–605.
30. Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011;134(Pt 2):396–404.
31. Meador KJ, Baker GA, Browning N, et al. Effects of fetal antiepileptic drug exposure: outcomes at 4.5 years. Neurology. 2012;78(16):1207–14.
32. Meador KJ, Baker GA, Browning N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–52.
33. Nadebaum C, Anderson V, Vajda F, et al. The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy. J Int Neuropsychol Soc. 2011;17(1):133–42.
34. Ogura H, Yasuda M, Nakamura S, et al. Neurotoxic damage of granule cells in the dentate gyrus and the cerebellum and cognitive deficit following neonatal administration of phenytoin in mice. J Neuropathol Exp Neurol. 2002;61(11):956–67.
35. Olney JW, Wozniak DF, Farber NB, et al. The enigma of fetal alcohol neurotoxicity. Ann Med. 2002;34(2):109–19.
36. Palac S, Meador K. Antiepileptic drugs and neurodevelopment: an update. Curr Neurol Neurosci Rep. 2011;11(4):423–7.
37. Pennell P. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be the safest? Epilepsia. 2008;49(Suppl 9):43–55.
38. Pennell P. Pregnancy, epilepsy, and women’s issues. Continuum (Minneap Minn). 2013;19(3):697–714.
39. Rasalam AD, Hailey H, Williams JH, et al. Characteristic of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol. 2005;47(8):551–5.
40. Reinisch JM, Sanders SA, Mortensen EL, et al. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA. 1995;274(19):1518–25.
41. Roullet FI, Wollaston L, Decatanzaro D, et al. Behavioral and molecular changes in the mouse in response to prenatal exposure to the anti-epileptic drug valproic acid. Neuroscience. 2010;170(2):514–22.
42. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA. 1994;271(10):767–70.
43. Shallcross R, Bromley RL, Cheyne CP, et al. In utero exposure to levetiracetam vs. valproate: development and language at 3 years of age. Neurology. 2014;82(3):213–21.
44. Shallcross R, Bromley RL, Irwin B, et al. Child development following in utero exposure: levetiracetam vs. sodium valproate. Neurology. 2011;76(4):383–9.
45. Stefovska VG, Uckermann O, Czuczwar M, et al. Sedative and anticonvulsant drugs suppress postnatal neurogenesis. Ann Neurol. 2008;64(4):434–45.
46. Sulzbacher S, Farwell JR, Temkin N, et al. Late cognitive effects of early treatment with phenobarbital. Clin Pediatr. 1999;38(7):387–94.
47. Turski CA, Ikonomidou C. Neuropathological sequelae of developmental exposure to antiepileptic and anesthetic drugs. Front Neurol. 2012;3:120.
48. Vanoverloop D, Schnell RR, Harvey EA, et al. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol. 1992;14(5):329–35.
49. Vinten J, Bromley RL, Taylor J, et al. The behavioral consequences of exposure to antiepileptic drugs in utero. Epilepsy Behav. 2009;14(1):197–201.
50. Wide K, Henning E, Tomson T, et al. Psychomotor development in pre-school children exposed to antiepileptic drugs in utero. Acta Paediatr. 2002;91(4):409–14.